Diabetes Mellitus Type 2
Conditions
Brief summary
Traditional diabetes therapies focus on improving blood sugar control. However, many studies show that this may not be enough. New treatments focusing on weight loss have heralded better results. One of these treatments is Semaglutide and the investigators wish to examine its effects further in this study. The investigators propose to investigate what happens to the fat inside the heart and the leg muscles.
Detailed description
Traditionally, diabetes therapies focus on improving glycaemic control. However, decades of well conducted clinical trials showed that glycaemic control alone has failed to reduce both all-cause and cardiovascular mortality in diabetes patients. The new diabetes treatment strategies of combining glucose control with weight reduction have heralded better cardiovascular outcomes, however their follow-up has been relatively short-term. The investigators propose to explore the effects of semaglutide administration plus dietary counselling and physical activity encouragement versus a more intensive strategy of semaglutide administration plus a personalised and supervised program of resistance and endurance exercise training.
Interventions
DRUGSemaglutide administration plus dietary counselling and physical activity encouragement
Semaglutide administration plus dietary counselling and physical activity encouragement
DRUGSemaglutide plus a personalised and supervised program of resistance and endurance training
Semaglutide administration plus a personalised and supervised program of resistance and endurance training.
Sponsors
University of Aberdeen
NHS Grampian
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Patients with a confirmed diagnosis of type 2 diabetes established in the previous 10 years between the ages of 20 and 75 * HbA1c ≥ 53 mmol/mol (7%) typically on diet and/or metformin/sulphonylureas (and/or sodium-glucose cotransporter-2 inhibitors, Dipeptidyl peptidase 4 inhibitors, thiazolidinediones, but not on insulin) * Patients who do not meet the WHO recommendations on physical activity (≤150 minutes per week) of moderate-vigorous physical activity (MVPA) * Patients who have a BMI of ≥27 but with a body weight of less than 140kgs due to limitations of the scanner table weight limit * Current or recent (within 3 months) eGFR \>30 mL/min/1.73m2) * Able to understand written and spoken English
Exclusion criteria
* Any previously unknown cardiac condition other than mild valvular disease * Any history of known coronary artery disease (including myocardial infarction and myocardial infarction with normal coronary arteries) * Any relevant or untreated endocrine condition (i.e. Cushings) * Impaired renal function (defined as estimated glomerular filtration rate of less than 30 mL/min/1.73m2) * Blood pressure of more than 180/100 mmHg * Patients on any other medication known to influence glucose or fatty acids metabolism (niacin, omega-3 fatty acids, other glucagon-like peptide-1 receptor agonists) * Patients with any dietary habits that may interfere with the investigation (for example high fat vegan diets, as we know form prior research that they have very different intramyocellular fat storage compared to those on no dietary preferences) * Patients with any history of any medical or surgical condition that in the judgement of the investigators may interfere with the exercise regime (i.e. peripheral vascular disease, arthritis), fatty acids metabolism (i.e. lipid storage diseases) or may compromise the safety of the participant (i.e. neurological syndromes for whom an intense exercise program could result in musculo-skeletal injury or accidents due to loss of balance). * Patients with a sensitivity to Semaglutide (known hypersensitivity, diabetic retinopathy, pregnancy, history of pancreatitis or history of any cancer) * Significant asthma or pulmonary disease * Participants unable to cycle on the ergometer * Unable to perform exercise testing (e.g. prosthetic limbs) * Pregnancy, breastfeeding or considering pregnancy. * Patients who have recently had gastrointestinal contrast or radionuclides * Inability to lie flat or remain motionless for scanning procedures * Patients whose girth size cannot allow them to fit in the magnetic resonance scanner (there is no set location to measure as this is different for everyone, but we have a plastic hoop that can be fitted around the largest circumference to check the fit) * Subjects who are not able to engage into a physical training regime or feel that they do not have the interest or sustained motivation to follow one. * Participants currently enrolled in other interventional clinical research * Participants not able to understand written or verbal English
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 1H-magnetic resonance spectroscopy | From enrollment to the end of treatment at the end of 12 weeks | Non-invasive proton magnetic resonance spectroscopy (1H MRS) for assessment to determine the total intramyocellular fat |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Intramyocellular lipid pool compartments | From enrollment to the end of treatment at the end of 12 weeks | Intramyocellular Lipid pool compartments examined with non-invasive proton magnetic resonance spectroscopy (1H MRS) and turnover examined with stable isotopes |
Countries
United Kingdom
Contacts
CONTACTAlexander Davidson, DM
CONTACTAmelia E Rudd, MSc, PhD
PRINCIPAL_INVESTIGATORDana Dawson, DM
University of Aberdeen
Outcome results
None listed